Skip to content

Still Climbin': An Intervention to Improve Coping Among Black Sexual Minority Men

Still Climbin': A Randomized Controlled Trial to Improve Coping, Medical Mistrust, and Healthcare Engagement Among Black Sexual Minority Men

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04587869
Enrollment
369
Registered
2020-10-14
Start date
2021-02-09
Completion date
2025-03-20
Last updated
2025-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Discrimination, Social, Health Care Utilization

Keywords

Black/African American sexual minority men

Brief summary

This study consists of a randomized controlled trial of a multi-session cognitive behavior therapy (CBT) group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM). Primary intervention objectives include increasing health care engagement and receipt of evidence-based preventive care, as well as better coping and reduced anticipated and internalized stigma, and medical mistrust among intervention participants.

Detailed description

This study is a randomized controlled trial of Still Climbin', an 8-session cognitive behavior therapy (CBT) group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM). Designed to be flexible for use in community settings, this intervention was developed in partnership with community stakeholders who emphasized the need for a community-based program outside of the health care system, and without a specific disease focus. It intends to give Black SMM a safe space to receive support for the whole of their identity and to openly discuss barriers to health care. Participants will be followed for 12 months. The effectiveness of the Still Climbin' intervention will be assessed on health care engagement and receipt of evidence-based preventive care, through surveys administered at multiple points throughout the intervention period. These outcomes will be confirmed with information from medical records. A total of 370 Black participants will be recruited and randomly assign 185 to receive the coping intervention and 185 to a no-treatment control. There will be about 10 groups of about 15 participants each for both intervention and control. Participants will be randomized to an intervention or control group after they complete the baseline survey. Participants will complete four surveys, starting with the baseline survey, and followed by 4-, 8-, and 12-month post-baseline follow-up surveys to assess health care engagement and receipt of evidence-based preventive care (e.g., cancer and diabetes screening, cardiovascular disease prevention, influenza vaccination, HIV prevention), and other topics such as coping strategies, stigma, and discrimination. The intervention is hypothesized to show increased health care engagement and receipt of evidence-based preventive care, in addition to better coping and reduced medical mistrust than the control group.

Interventions

A cognitive behavior therapy group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).

Sponsors

University of Massachusetts, Boston
CollaboratorOTHER
University of Southern California
CollaboratorOTHER
APLA Health
CollaboratorUNKNOWN
RAND
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

Outcomes assessor does not randomize participant until after the baseline assessment

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years of age or older * Biologically male at birth * Identify as male * Self-identify as a Black/African American * Report having sex with men in the past 24 months * Anticipate being available for the next 12 months to attend study visits * Able to interact and communicate in written and spoken English.

Exclusion criteria

* Unwilling/Unable to provide informed consent * Cisgender women * Transgender women * Transgender men

Design outcomes

Primary

MeasureTime frameDescription
Inadequate Healthcare Utilizationbaseline to 12-month post-baselineIndicator that the individual reported (1) fewer than 1 ambulatory visit AND (2) at least 1 emergency department visit (without subsequent hospitalization) or at least 1 hospitalization in the past 4 months at any of the 3 follow-up assessments (4, 8, and 12 months post-baseline)
Proportion of Evidence-based Care Components Received Across Follow-up Assessmentsbaseline to 12 months post-baselineFor each individual, this measure is the number of components that were received at any time across the 3 follow-up assessments divided by the number of components they were eligible for at any time across the 3 follow-up assessments, expressed as a proportion. 25 components were evaluated and eligibility for each component varies by individual and follow-up period.

Secondary

MeasureTime frameDescription
Adaptive Coping Strategies (Social Support Seeking)4-, 8-, and 12-months post-baselineAverage adaptive coping rating on the Brief COPE scale, social support items (higher=better coping; range=1-4)

Countries

United States

Participant flow

Participants by arm

ArmCount
Intervention
The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM). CBT Coping Intervention: A cognitive behavior therapy group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).
171
No-treatment Control
Participants who are assigned to the control group will not receive the intervention.
198
Total369

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDeath10
Overall StudyGrant Termination1325
Overall StudyLost to Follow-up2734
Overall StudyOther10
Overall Studytoo busy20
Overall StudyWithdrawal by Subject22

Baseline characteristics

CharacteristicTotalNo-treatment ControlIntervention
Adaptive coping (social support seeking)2.61 units on a 4-point scale (range 1-4)
STANDARD_DEVIATION 0.92
2.57 units on a 4-point scale (range 1-4)
STANDARD_DEVIATION 0.92
2.65 units on a 4-point scale (range 1-4)
STANDARD_DEVIATION 0.91
Age, Continuous44.73 years
STANDARD_DEVIATION 12.78
44.73 years
STANDARD_DEVIATION 12.37
44.73 years
STANDARD_DEVIATION 13.27
Inadequate healthcare utilization88 Participants53 Participants35 Participants
Proportion of evidence-based care components received0.60 proportion
STANDARD_DEVIATION 0.22
0.60 proportion
STANDARD_DEVIATION 0.22
0.59 proportion
STANDARD_DEVIATION 0.22
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
356 Participants190 Participants166 Participants
Race (NIH/OMB)
More than one race
13 Participants8 Participants5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants
Region of Enrollment
United States
369 participants198 participants171 participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
369 Participants198 Participants171 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 1710 / 198
other
Total, other adverse events
0 / 1710 / 198
serious
Total, serious adverse events
22 / 17117 / 198

Outcome results

Primary

Inadequate Healthcare Utilization

Indicator that the individual reported (1) fewer than 1 ambulatory visit AND (2) at least 1 emergency department visit (without subsequent hospitalization) or at least 1 hospitalization in the past 4 months at any of the 3 follow-up assessments (4, 8, and 12 months post-baseline)

Time frame: baseline to 12-month post-baseline

Population: The outcome is missing for all participants (n=53) who did not participate in any follow-up surveys (nonresponse weights were used to account for potential bias). The outcome was never missing among those who participated in any follow-up surveys.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
InterventionInadequate Healthcare Utilization41 Participants
No-treatment ControlInadequate Healthcare Utilization39 Participants
Comparison: Nonresponse weights were employed to account for potential bias from excluding participants who did not complete any follow-up assessments.p-value: 0.4495% CI: [0.73, 2.07]Regression, Logistic
Primary

Proportion of Evidence-based Care Components Received Across Follow-up Assessments

For each individual, this measure is the number of components that were received at any time across the 3 follow-up assessments divided by the number of components they were eligible for at any time across the 3 follow-up assessments, expressed as a proportion. 25 components were evaluated and eligibility for each component varies by individual and follow-up period.

Time frame: baseline to 12 months post-baseline

Population: The outcome is missing for all participants (n=53) who did not participate in any follow-up surveys (nonresponse weights were used to account for potential bias). The outcome was never missing among those who participated in any follow-up surveys.

ArmMeasureValue (MEAN)Dispersion
InterventionProportion of Evidence-based Care Components Received Across Follow-up Assessments.46 proportionStandard Deviation 0.22
No-treatment ControlProportion of Evidence-based Care Components Received Across Follow-up Assessments.47 proportionStandard Deviation 0.23
Comparison: Nonresponse weights were employed to account for potential bias from excluding participants who did not complete any follow-up assessments.p-value: 0.47Regression, Linear
Secondary

Adaptive Coping Strategies (Social Support Seeking)

Average adaptive coping rating on the Brief COPE scale, social support items (higher=better coping; range=1-4)

Time frame: 4-, 8-, and 12-months post-baseline

Population: The outcome is missing for all participants (n=53) who did not participate in any follow-up surveys. The outcome is missing for an additional n=10 (3.2%) participants who did not complete any of the 4 survey items included in the scale.~Because this measure was analyzed in a repeated measures regression framework where each participant may contribute up to 3 observations (and may or may not complete each assessment), the sample size varies by assessment.

ArmMeasureGroupValue (MEAN)Dispersion
InterventionAdaptive Coping Strategies (Social Support Seeking)4-month assessment2.60 units on a scale (range 1-4)Standard Deviation 0.96
InterventionAdaptive Coping Strategies (Social Support Seeking)8-month assessment2.77 units on a scale (range 1-4)Standard Deviation 0.96
InterventionAdaptive Coping Strategies (Social Support Seeking)12-month assessment2.61 units on a scale (range 1-4)Standard Deviation 0.92
No-treatment ControlAdaptive Coping Strategies (Social Support Seeking)4-month assessment2.50 units on a scale (range 1-4)Standard Deviation 0.96
No-treatment ControlAdaptive Coping Strategies (Social Support Seeking)8-month assessment2.56 units on a scale (range 1-4)Standard Deviation 0.92
No-treatment ControlAdaptive Coping Strategies (Social Support Seeking)12-month assessment2.41 units on a scale (range 1-4)Standard Deviation 0.91
Comparison: Unlike the two primary outcomes which have a single value for each participant, for this outcome we employed a repeated measures style structure with one record for each of up to 3 FU observations. A sandwich estimator (SAS Proc Surveyreg) was employed to account for clustering of observations within participant. In addition, nonresponse weights were employed to account for potential bias from excluding participants who did not complete any follow-up assessments.p-value: 0.02Regression, Linear

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026